Travere Therapeutics (TVTX) Tops Q1 EPS by 115c

Travere Therapeutics (NASDAQ: TVTX) reported Q1 EPS of ($0.09), $1.15 better than the analyst estimate of ($1.24). Revenue for the quarter came in at $44 million versus the consensus estimate of $50.6 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• JPMorgan Reinstates Dauch Corporation (DCH) at Neutral
• AbbVie updates 2026 EPS guidance after $291M IPR&D charge